Diligence memo · auto-generated · as of July 2, 2026
Immune Pharmaceuticals Inc
Immune Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Immune Pharmaceuticals Inc operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immune Pharmaceuticals Inc has raised $12M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2014-03-14.
Most recent recorded round closed around 2014-03-14.
Valuation (modeled)modeled
Provath models Immune Pharmaceuticals Inc at approximately $363M (range $13M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.85× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 57% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.